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- Alzheimer’s Disease (AD) is one of the most common forms of dementia and neurodegenerative disease from nowadays. It was first described more 
than 100 years ago by Dr. Alois Alzheimer and it still hasn’t got a cure. 
- It is molecular characterized by progressive accumulation of misfolded proteins with the formation of toxic oligomers.  
- AD has three manifestations, going from mild (preclinical), mild cognitive impaired (MCI) and finally to severe (dementia). Once reached this last 
stage, patients are disabled: work and daily activity, such as getting dressed, is impaired. 
Abstract 
 
    
How Alzheimer’s Disease is generated 
Obtained and adapted from “Temas 62, Investigación y Ciencia, 2010” 
 
Aβ1-42 peptides 
are  released to 
the extracellular 
space 
 
 
Aβ1-42 peptides 
aggregate and 
form amyloid 
plaques 
 
 
Amyloid plaques interact with 
AMPA channels, 
transforming their structure 
and becoming permanently 
open 
 
 
 
Opened AMPA channels 
allow massive Ca2+ 
entrance inside the 
neuron 
 
 
 If calcium levels remain 
elevated, Ca2+ induces 
kinases hyper-activation 
and Tau proteins starts 
being 
hyperphosphorilated   
 Hyperphosphorilated tau 
is unable to stabilize 
microtubules, 
cytoskeleton loses its 
structure and neuronal 
tangles get formed 
 
- Amyloid Precursor Protein (APP): 
- Transmembranal protein encoded at 
chromosome 21. 
- Depending on splicing processes, it 
might form a normal peptide or toxic 
peptide (Aβ1-42). 
- Toxic peptides generate amylogenic 
plaques and cause neuronal death. 
- Presenilines 1 and 2 (PSEN1, PSEN2): 
- Both presenilines encode the γ-
secretase catalytic centre, so 
mutations on theses genes might 
increase the proportion of Aβ1-42. 
- Tau Protein: when hyperphosphorylated 
it induces formation of neurofibrillary 
tangles. 
- Apolipoprotein E (apoE): 
- Cholesterol transporter, responsible 
for the neuronal membrane’s repair 
and modification. 
- Different alleles: ε3 (most common), 
ε2 (protective for AD) and ε4 (risk 
factor for AD). 
Involved Molecules 
APP processing: Normal and Amylogenic pathway 
 
 
- Body generates it’s own antibodies: 
vaccination strategy. 
- CAD106 (Novartis®), ABvac40 and 
ABvac42 (Araclon Biotech®) vaccines. 
 
 
Active Immune 
Therapy 
 
 
 
- Based on the utilization of monoclonal 
antibodies: high specificity antigen-
antibody 
- Three possible action mechanisms of 
monoclonal antibodies: 
1. Anti-Aβ cross the hemathoencephalic 
barrier, recognize the amyloid plaques 
and eliminate them. 
2. Anti-Aβ activate the microglia and 
phagocytosis of Aβ, mediated by Fc 
receptors. 
3. Descent of peripheral Aβ by altering the 
flux from brain to plasma. 
- Bapineuzumab (didn’t report significant 
effect) and Solanezumab (ongoing 
research). 
 
 
 
 
 
Passive Immune 
Therapy  
 
Alzheimer’s disease is a complex 
pathology. Nowadays, the only effective 
strategy consists on premature 
detection, and administration of 
cholinesterase inhibitory treatment in 
order to slow down the apparition of the 
memory loss. 
 
Most of the actual ongoing clinical trials 
are based on active and passive 
immune therapy, where patients require 
a periodic vaccination. Some of these 
trials will have results soon, such as 
those performed by Araclon Biotech® 
or based on Solanezumab. 
 
The worldwide spread of Alzheimer's 
and the increased life-expectancy in 
developed countries turns this 
pathology into one of the most 
important epidemics of the 21st century,  
promoting companies to investigate it. 
Alzheimer’s disease treatments have a 
promising pipeline, with a wide range of 
clinical trials and research ongoing that 
might give hope to those patients who 
otherwise would have no choice. 
 
Conclusions 
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